Welcome to Herceptin® Access Solutions™

At Genentech, we develop medicines like Herceptin® (trastuzumab) for serious or life-threatening medical conditions and we believe they should be accessible for the patients who need them.

Health insurance coverage and reimbursement issues can be confusing and challenging. Herceptin Access Solutions is here to make the process as easy as possible.

Please select one of the following so that we can direct you to information that is most appropriate for you.

  • Herceptin Access Solutions for Patients/Caregivers
  • Herceptin Access Solutions for HCPs


Please note: This description is provided for informational purposes only. The submission and completion of reimbursement- or coverage-related documentation are the responsibility of the patient and health care provider. Genentech, Inc. makes no representation or guarantees concerning reimbursement or coverage for any service or item.

Herceptin (trastuzumab) Indications

Adjuvant indications: Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature)* breast cancer:

  • As part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
  • With docetaxel and carboplatin
  • As a single agent following multi-modality anthracycline-based therapy

*ER/PR-negative, tumor size >2 cm, age <35 years, or histological and/or nuclear grade 2 or 3.

Metastatic indications: Herceptin is indicated:

  • In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer
  • As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease

Herceptin Boxed WARNINGS and Additional Important Safety Information

Herceptin administration can result in sub-clinical and clinical cardiac failure manifesting as congestive heart failure and decreased left ventricular ejection fraction. Serious infusion reactions and pulmonary toxicity have occurred; fatal infusion reactions have been reported. Exacerbation of chemotherapy-induced neutropenia has also occurred. Herceptin can cause oligohydramnios and fetal harm when administered to a pregnant woman. The most common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.

Please see the Herceptin full prescribing information including Boxed WARNINGS and additional important safety information.